Kyungok-go for fatigue in patients with long COVID: Double-blind, randomized, multicenter, pilot clinical study protocol
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0319459 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift PLOS ONE, 2025. Verfasst von Jiwon Yoon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Korean Medicine Data Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea. Hauptthemen laut MEDLINE: Fatigue, Plant Extracts, Post-Acute COVID-19 Syndrome, Drugs, Chinese Herbal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Institute of Oriental Medicine.
Abstract (Originalsprache)
The most common symptom reported by patients after recovery from coronavirus disease 2019 (COVID-19) is fatigue. However, robust clinical evidence supporting the effectiveness of treatments and interventions for fatigue in COVID-19 survivors is lacking. This pilot clinical trial aims to assess the safety and efficacy of Kyungok-go, a herbal preparation targeting fatigue, in patients after recovering from COVID-19. The study will include 100 participants with persistent fatigue for more than 12 weeks after COVID-19 recovery. They will be randomly allocated into two groups: the Kyungok-go group (n = 50) and the placebo group (n = 50). Kyungok-go or placebo will be administered twice daily for 12 weeks, and the participants will be assessed at 4-week intervals. The primary outcome will be the change in the Fatigue Severity Scale score. Secondary outcomes will include cognitive function, physical function, quality of life, depression, sleep quality, medication adherence, and feasibility. This study is the first attempt to investigate the safety and efficacy of Kyungok-go for relieving fatigue related to long COVID. The results are expected to contribute to the establishment of a knowledge base and reveal the potential of herbal medicine prescriptions for managing and recovering from the most common sequelae of COVID-19. Trial registration number: KCT0008789 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Korean Medicine Data Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea.
- Department of Medical Classics, College of Korean Medicine, Daejeon University, Daejeon, Republic of Korea.
- Department of Oriental Neuropsychiatry, Dong-eui University College of Korean Medicine, Busan, Republic of Korea.
- Department of Acupuncture & Moxibustion, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
- Korean Medicine Clinical Trial Center, Korean Medicine Hospital, Kyung Hee University, Seoul, Republic of Korea.
- Korean Medicine Convergence Research Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea.
ORCID-Profile: Jiwon Yoon, Sanghyun Kim, Sunoh Kwon
Förderung
- Korea Institute of Oriental Medicine
Zitieren
APA
Yoon, J., Kim, S., Kwon, C. Y., Kang, J. W., Kim, T. H., & Kwon, S. (2025). Kyungok-go for fatigue in patients with long COVID: Double-blind, randomized, multicenter, pilot clinical study protocol. PLOS ONE. https://doi.org/10.1371/journal.pone.0319459
Vancouver
Yoon J, Kim S, Kwon CY, Kang JW, Kim TH, Kwon S. Kyungok-go for fatigue in patients with long COVID: Double-blind, randomized, multicenter, pilot clinical study protocol. PLOS ONE. 2025. doi:10.1371/journal.pone.0319459
BibTeX
@article{Yoon2025,
author = {Yoon, Jiwon and Kim, Sanghyun and Kwon, Chan-Young and Kang, Jung Won and Kim, Tae-Hun and Kwon, Sunoh},
title = {Kyungok-go for fatigue in patients with long COVID: Double-blind, randomized, multicenter, pilot clinical study protocol},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0319459}
}
EUVIMED